Reata Pharmaceuticals, Inc.
http://www.reatapharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Reata Pharmaceuticals, Inc.
Flat Is The New Up As Biogen Anticipates Stabilizing Product Revenue In 2024
With its multiple sclerosis legacy under various pressures but four new drugs in indications outside of MS, the company expects flat product revenue in 2024 after a 3.8% decline in 2023.
Biogen’s Skyclarys Seals Important Next Step With EU Approval
Friedreich’s ataxia is particularly prevalent in Europe, and the company hopes to replicate the fast US uptake for Skyclarys there.
Biogen’s Singhal Offers A Look Into Company's Pipeline Review
Priya Singhal, head of development, spoke with Scrip about the company’s R&D restructuring, readouts coming from the culled pipeline and how Biogen is thinking about adding to it in the future.
Less Than First: Below-Average Innovation In US FDA’s Big 2023 Novel Approval Haul
Innovation metrics like first-in-class and breakthrough therapy approvals declined as a share of novel agents in 2023, even as the US FDA’s drugs center posted one of its biggest novel approval totals ever.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice